Star Combo Pharma Ltd (S66) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Star Combo Pharma Ltd (S66) has a cash flow conversion efficiency ratio of 0.015x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (AU$575.23K ≈ $407.01K USD) by net assets (AU$38.68 Million ≈ $27.37 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see Star Combo Pharma Ltd market capitalisation for the company's overall valuation and market capitalisation.
Star Combo Pharma Ltd - Cash Flow Conversion Efficiency Trend (2016–2025)
This chart illustrates how Star Combo Pharma Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Star Combo Pharma Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Star Combo Pharma Ltd ranked by their cash flow conversion efficiency. Explore Star Combo Pharma Ltd (S66) cash earnings ratio to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
AroCell AB
ST:AROC
|
-0.010x |
|
Radius Gold Inc.
V:RDU
|
-0.098x |
|
Terragen Holdings Ltd
AU:TGH
|
-0.330x |
|
Serica Energy PLC
LSE:SQZ
|
0.080x |
|
Mynd.ai, Inc.
NYSE MKT:MYND
|
-0.360x |
|
Vertex Resource Group Ltd
V:VTX
|
0.187x |
|
Future Retail Limited
NSE:FRETAIL
|
1.043x |
|
Yong Tai Bhd
KLSE:7066
|
0.005x |
Annual Cash Flow Conversion Efficiency for Star Combo Pharma Ltd (2016–2025)
The table below shows the annual cash flow conversion efficiency of Star Combo Pharma Ltd from 2016 to 2025. View S66 live share price for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-06-30 | AU$38.26 Million ≈ $27.07 Million |
AU$11.94 Million ≈ $8.45 Million |
0.312x | +3404.96% |
| 2024-06-30 | AU$33.51 Million ≈ $23.71 Million |
AU$-316.45K ≈ $-223.91K |
-0.009x | -116.74% |
| 2023-06-30 | AU$33.26 Million ≈ $23.53 Million |
AU$1.88 Million ≈ $1.33 Million |
0.056x | +2193.37% |
| 2022-06-30 | AU$35.41 Million ≈ $25.05 Million |
AU$87.11K ≈ $61.64K |
0.002x | -73.14% |
| 2021-06-30 | AU$36.19 Million ≈ $25.61 Million |
AU$331.53K ≈ $234.58K |
0.009x | +140.03% |
| 2020-06-30 | AU$44.50 Million ≈ $31.49 Million |
AU$-1.02 Million ≈ $-720.42K |
-0.023x | +79.06% |
| 2019-06-30 | AU$20.00 Million ≈ $14.15 Million |
AU$-2.19 Million ≈ $-1.55 Million |
-0.109x | +3.35% |
| 2018-06-30 | AU$16.26 Million ≈ $11.50 Million |
AU$-1.84 Million ≈ $-1.30 Million |
-0.113x | -290.16% |
| 2017-06-30 | AU$15.68 Million ≈ $11.10 Million |
AU$932.20K ≈ $659.59K |
0.059x | -82.19% |
| 2016-06-30 | AU$3.88 Million ≈ $2.75 Million |
AU$1.30 Million ≈ $917.50K |
0.334x | -- |
About Star Combo Pharma Ltd
Star Combo Pharma Limited manufactures and distributes health food products and nutritional supplements in Australia and China. It operates in two segments, OEM and Retail. The company develops, manufactures, markets, and sells natural health supplements and skin care products. It also provides its products through e-commerce platform to Chinese health product consumers. The company sells its pro… Read more